VOLUME 30 1988

SUBJECT INDEX

Acquisition, 949
  retention
  scopolamine
  T-maze, 14-unit
Active avoidance, 77
  aminergic neurotransmitter systems
  memory retrieval
  pharmacological stimulation
Activity meter, 199
  motor development
  nicotine
  prenatal changes
Acute administration
  amphetamine, 871
  behavioral effects, 809
  caffeine, 809
  chronic administration, 809
  ethanol, 769
  latent inhibition disruption, 871
  MHPG-SO_4, 769
  noradrenaline metabolism, 769
  strain differences, 769
Acute effects, 737
  behavioral tolerance
  chronic effects
  cocaine
  complex operant behavior
  dose-dependent effects
  monkeys
Acute pretreatment, 1065
  nicotine
  plasma corticosterone levels
  strain differences
Acute response, 269
  genetic influence
  nicotine
  nicotine tolerance
Adenosine, 155
  cerebellum
  ethanol
  motor incoordination
  spontaneous motor activity inhibition
Adenosine receptor downregulation, 303
  brain, rat
  chronic administration
  diazepam
Adenosine receptors, 707
  autoradiography
  methylxanthines
  strain differences
Ad lib feeding, 649
  body weight restriction
  dorsomedial hypothalamic nucleus
  food restriction
  lesions, dorsomedial hypothalamic nucleus
Adrenalectomy
  analgesia, stress-induced, 791
  corticosterone, 101
  H_2-receptor, 791
  hypophysectomy, 791
  schedule-induced wheel running, 101
(1–24)Adrenocorticotropic hormone, 391
  atria, rat
  ^{3}H-norepinephrine uptake
Aggression, 409
  carbamazepine
  cats
  midbrain periaqueductal gray
Aggressive behavior
  alphaxalone, 729
  comparative effects, 729
  locomotor behavior, 729
  medroxyprogesterone acetate, 829
  mice, male, 829
  progesterone, 729
  reproductive behavior, 729
  tamoxifen, 829
Alcohol intake, 823
  renin-angiotensin system
  serotonin uptake inhibitor
N-Allylnormetazocine, 493
  oral self-administration
  phencyclidine
  rhesus monkeys
  withdrawal
Alpha-adrenoceptors, 471
  biphasic effects
  clonidine
  conflict behavior
Alphaxalone, 729
  aggressive behavior
  comparative effects
  locomotor behavior
  progesterone
  reproductive behavior
Alprazolam, 511
  low-dose administration
  motor activity
Aminergic neurotransmitter systems, 77
  active avoidance
  memory retrieval
  pharmacological stimulation
α-Amino-3-hydroxy-5-methylisoxazole-4-propionate, 379
  hypermotility
  nucleus accumbens
  quisqualic acid receptors
Amnesia
  MK-801,205
  retrieval, 1093
  scopolamine, 1093
Amphetamine
  acute administration, 871
  amphetamine anorexia, 641
  anorectic effects, 755
  behavioral microanalysis, 641
  cholecystokinin-octapeptide, 309
  chronic administration, 899
  circadiam rhythm, 535
  continuous administration, 535
  dopamine, 641
  drug interactions, 641
  EEG power spectra, 489
  hyperlocomotion, 309
  intra-accumbens injection, 309
  intracerebroventricular injection, 309
  latent inhibition disruption, 871
  locomotor behavior, 535
  motor activity, 489
  opiate mechanisms, 755
  route of administration, 309
  stereotypy, 309, 535, 899
  tolerance development, 755
  U50488H, 755
d-Amphetamine
  γ-butyrolactone, 45
  CGS 10746B, 1089
  conditioned place preference, 853
  diazepam, 853
  drug discrimination, 1085, 1089
  drug interactions, 45, 853
  lever pressing, 45
  morphine, 853
  naloxone, 45
  nisoxetine, 1085
  ritanserin, 853
Amphetamine anorexia, 641
  amphetamine
  behavioral microanalysis
  dopamine
  drug interactions
Analepsis, 115
  codeine
  rat/rabbit comparisons
Analgesia
  bremazocine, 817
  ethylketocyclazocine, 817
  intestinal inhibition, 319
  morphine, 123, 319
  neonatal administration, 817
  prenatal stress, 123
  sex differences, 123
  supraspinal cerebral areas, 319
Analgesia, morphine-induced, 905
  jumping, naloxone-induced
  morphine
  naloxone
  restraint
Analgesia, stress-induced, 791
  adrenalectomy
  H_2-receptor
  hypophysectomy
Anatomical analysis, 129
  carbachol
  frontal cortex
  motor seizures
Angiotensins, 343
  blood pressure responsiveness
  genetic breeding
  intracarotid infusion
Anorectic effects, 755
  amphetamine
  opiate mechanisms
  tolerance development
  U50488H

Anorexia, 89
dexfenfluramine
ischymetric mechanisms
lipostatic mechanisms
metabolic chamber
Antagonist treatment, 443
heroin
intravenous self-administration
nucleus accumbens
periaqueductal grey
Antinociception, 65
bradycardia
hypotension
intrathecal antagonists
intravenous administration
[D-Ala²]-methionine enkephalinamide
Anxiety, 701
benzodiazepine receptors
drug interactions
ethanol
plus-maze test
Anxiogenic effects, 331
benzodiazepine receptors
brain, rat
N-butyl β carboline-3-carboxylate
proconvulsant effects
Anxiolytic identification, 775
conditioned defensive burying
Anxiolytics, 1071
buspirone
chlordiazepoxide
defensive burying
drug comparisons
shock-probe test
Apomorphine
body temperature, 683
climbing behavior, 143
dose-dependent effects, 107
genetic analysis, 143
haloperidol, 683
locomotor behavior, 143
passive avoidance learning, 107
punished responding, 753
SCH 23390, 683
unpunished responding, 753
Apparatus
eight-arm radial maze, 119
metabolic chamber, 89
Morris Water Maze, 519
osmotic mini-pump, 357
T-maze, 14-unit, 949
Approach response, 397
differential effects
electrical stimulation
escape response
intracerebral microinjection
lateral hypothalamus
morphine
Asymmetrical activation, 911
cerebral cortex
GABA-gated chloride channels
Atria, rat, 391
(1–24)adrenocorticotropic hormone
³H-norepinephrine uptake
Atropine, 625
chickens
immobility response
scopolamine
strain differences
Auditory stimulus, 983
functional neuroanatomy
heroin
Autoradiography
adenosine receptors, 707
brain regional uptake, 781
2-deoxyglucose, 781
ethanol, 781
methylxanthines, 707
strain differences, 707, 781
Aversive effects, 693
dopamine innervation
lesions, 6-OHDA
opiates
visceral cortex

Behavioral effects
acute administration, 809
caffeine, 809
chronic administration, 809
5-methoxytryptamine, 847
parachlorophenylalanine, 847
prenatal exposure, 847
serotonin uptake, 847
thyrotropin-releasing hormone binding, 73
triazolobenzodiazepines, 73
Behavioral/electrocorticographic comparisons, 479
diazepam
drug interactions
pentylenetetrazol
rat pups
Behavioral microanalysis, 641
amphetamine
amphetamine anorexia
dopamine
drug interactions
Behavioral tolerance, 737
acute effects
chronic effects
cocaine
complex operant behavior
dose-dependent effects
monkeys
Benzodiazepine binding sites, 679
in vitro autoradiography
substantia innominata
Benzodiazepine receptor binding affinity, 665
3-hydroxykynurenine
neonatal deficiency
seizures
vitamin B-6
Benzodiazepine receptors
anxiety, 701
anxiogenic effects, 331
brain, rat, 331
N-butyl β carboline-3-carboxylate, 331
drug interactions, 701
ethanol, 701
plus-maze test, 701
proconvulsant effects, 331
Benzodiazepines
chlordiazepoxide, 515
hunger-mimetic model, 515
hyperphagia, 515
postdecapitation convulsions, 1101
tonic component, 1001
Bicuculline, 337
flight behavior
microinjection
rats, detelencephalated
semicarbazide
Binding characteristics, 255
nicotinic ligands
pharmacologic analysis
Biodisposition, 371
charcoal
phencyclidine
Biogenic amines, 795
discrete brain regions
high performance liquid chromatography
Biphasic effects, 471
alpha-adrenoceptors
clonidine
conflict behavior
Blood pressure responsiveness, 343
angiotensins
genetic breeding
intracarotid infusion
Body temperature
apomorphine, 683
cannabidiol, 675
cannabinol, 675
chronic treatment, 451
dose-dependent effects, 451
drug interactions, 451, 675
haloperidol, 683
8-OH-DPAT, 451
open-field activity, 675
SCH 23390, 683
Body weight restriction, 649
ad lib feeding
dorsomedial hypothalamic nucleus
food restriction
lesions, dorsomedial hypothalamic nucleus
Bradycardia, 65
antinociception
hypotension
intrathecal antagonists
intravenous administration
[D-Ala²]-methionine enkephalinamide
Brain
amygdala, 129, 319, 769
brain stem, 137
bulbar reticular formation, 319
caudate, 319
caudate-putamen, 325
cerebellum, 155
cerebral cortex, 137, 669, 769, 911, 941
dorsal hypothalamus, 319
dorsal noradrenergic bundle, 835
dorsal periaqueductal gray, 337
dorsomedial hypothalamic nucleus, 649
frontal cortex, 129, 319
hippocampus, 117, 769
hypothalamic paraventricular nucleus, 925
hypothalamus, 769, 941
lateral hypothalamus, 319, 365, 397, 657, 917
lateral ventricle, 519
locus coeruleus, 13, 769
midbrain, 941
medial anterior cortex, 129
medial forebrain bundle-lateral hypothalamus, 195
medial hypothalamus, 337
median raphe nucleus, 529, 577
midbrain periaqueductal gray, 409
mid-line thalamus, 319
nucleus accumbens, 189, 309, 379, 443, 1051

nucleus basalis of Meynert, 129
periaqueductal gray, 319, 443
raphe magnus nucleus, 319
striatum, 137, 457
ventral tegmentum, 1077
visceral cortex, 693
Brain, rat
adenosine receptor downregulation, 303
anxiogenic effects, 331
benzodiazepine receptors, 331
N-butyl β carboline-3-carboxylate, 331
chronic administration, 303
diazepam, 303
hypothermia, 941
proconvulsant effects, 331
thyrotropin-releasing hormone, 941
Brain regional uptake, 781
autoradiography
2-deoxyglucose
ethanol
strain differences
Brain-stimulation reward, 195
buprenorphine
reinforcing properties
reward threshold
Bremazocine, 817
analgesia
ethylketocyclazocine
neonatal administration
4-Bromo-2,5-dimethoxyphenethylamine, 597
drugs of abuse
Buprenorphine
brain-stimulation reward, 195
differential tolerance, 977
diprenorphine, 977
drug comparisons, 977
food intake, 977
heroin, 977
monkeys, 977
reinforcing properties, 195
reward threshold, 195
Buspirone
anxiolytics, 1071
chlordiazepoxide, 1071
defensive burying, 1071
drug comparisons, 1071
gepirone, 723
8-hydroxy-2-(di-n-propylamino)tetralin, 723
pigeons, 723
shock-probe test, 1071
unpunished responding, 723
N-Butyl β carboline-3-carboxylate, 331
anxiogenic effects
benzodiazepine receptors
brain, rat
proconvulsant effects
γ-Butyrolactone, 45
d-amphetamine
drug interactions
lever pressing
naloxone

Caffeine, 809
acute administration
behavioral effects
chronic administration
Cannabidiol, 675
body temperature
cannabinol
drug interactions
open-field activity
Cannabinol, 675
body temperature
cannabidiol
drug interactions
open-field activity
Carbachol, 129
anatomical analysis
frontal cortex
motor seizures
Carbamate esters, 403
nicotine
nicotine agonists
nicotine antagonists
structure-activity studies
Carbamazepine, 409
aggression
cats
midbrain periaqueductal gray
β-Carbolines, 351
drug discrimination
FG 7142
footshock
novel environment
Catalepsy, 765
dopamine receptor
dose-dependent effects
drug interactions
LY7155
Catecholamines, 589
drug interactions
endogenous opioids
self-stimulation reward
ventral tegmental area
Cats
aggression, 409
carbamazepine, 409
midbrain periaqueductal gray, 409
naloxone, 543
penile erection, 543
Central benzodiazepine agonist, 749
clonazepam
drug comparisons
NaCl intake
peripheral benzodiazepine agonist
RO 5-4864
Central nicotinic receptors, 235
conditioned taste aversion
discriminative stimulus
nicotine
Cerebellum, 155
adenosine
ethanol
motor incoordination
spontaneous motor activity inhibition
Cerebral cortex, 911
asymmetrical activation
GABA-gated chloride channels
Cerebral depletion, 137
conditioned avoidance responding
norepinephrine
CGS 10746B, 1089
d-amphetamine
drug discrimination
Charcoal, 371
biodisposition
phencyclidine
Chemoconvulsants, 995
drug interactions
GABAergic drugs
pentobarbital
phenobarbital
Chickens, 625
atropine
immobility response
scopolamine
strain differences
Chlordiazepoxide
anxiolytics, 1071
benzodiazepines, 515
buspirone, 1071
chronic intake, 385
contextual fear, 209
cross-tolerance, 385
defensive burying, 1071
drug comparisons, 1071
ethanol, 385
ethanol tolerance, 385
hunger-mimetic model, 515
hyperphagia, 515
nociception, 209
shock controllability, 209
shock-probe test, 1071
Cholecystokinin, 569
dose-dependent effects
rate-decreasing effects
schedule-controlled behavior
Cholecystokinin-octapeptide, 309
amphetamine
hyperlocomotion
intra-accumbens injection
intracerebroventricular injection
route of administration
stereotypy
Chronic administration
acute administration, 809
adenosine receptor downregulation, 303
amphetamine, 899
behavioral effects, 809
brain, rat, 303
caffeine, 809
clorgyline, 299
desmethylimipramine, 299
diazepam, 303
l-dopa, 585
drinking, 299
eating, 299
haloperidol, 585
rebound enhancement, 585
self-stimulation, 585
stereotyped behavior, 899
Chronic effects, 737
acute effects
behavioral tolerance
cocaine
complex operant behavior
dose-dependent effects
monkeys
Chronic intake, 385
chlordiazepoxide
cross-tolerance
ethanol
ethanol tolerance
Chronic stress, 169
[^{3}H]cyclohexyladenosine
hypothalamus
receptor ligand binding
Chronic treatment, 451
body temperature
dose-dependent effects
drug interactions
8-OH-DPAT

Circadian rhythm, 535
amphetamine
continuous administration
locomotor behavior
stereotypy
Circadian studies, 347
clorgyline
5-hydroxytryptamine receptors
Circling behavior, 1077
dopaminergic uptake blocker
morphine
Citalopram, 613
discriminative stimulus
drug comparisons
l-5-hydroxytryptophan
RO 4-46202
Classical conditioning, 433
CS-UCS interval
d-lysergic acid diethylamide
reflex facilitation
Classical trace conditioning, 427
d-lysergic acid diethylamine
Clenbuterol, 417
investigatory behavior
locomotor activity
peripheral mediation
Climbing behavior, 143
apomorphine
genetic analysis
locomotor behavior
Clonazepam, 749
central benzodiazepine agonist
drug comparisons
NaCl intake
peripheral benzodiazepine antagonist
RO 5-4864
Clonidine
alpha-adrenoceptors, 471
biphasic effects, 471
conflict behavior, 471
feeding behavior, 925
Clorgyline
chronic administration, 299
circadian studies, 347
desmethylimipramine, 299
drinking, 299
eating, 299
5-hydroxytryptamine receptors, 347
Clozapine, 603
drug comparisons
fixed-consecutive-number responding
Cocaine
acute effects, 737
behavioral tolerance, 737
chronic effects, 737
complex operant behavior, 737
dose-dependent effects, 737
imipramine, 1
interactive effects, 1
monkeys, 737
self-stimulation, 1
train-duration thresholds, 1
Codeine, 115
analepsis
rat/rabbit comparisons
Comparative effects, 729
aggressive behavior, 729
alphaxalone
locomotor behavior
progesterone
reproductive behavior
Complex operant behavior, 737
acute effects
behavioral tolerance
chronic effects
cocaine
dose-dependent effects
monkeys
Conditioned avoidance responding, 137
cerebral depletion
norepinephrine
Conditioned defensive burying, 775
anxiolytic identification
Conditioned place preference
d-amphetamine, 853
diazepam, 853
drug interactions, 853
hippocampus, 787
morphine, 787, 853
ritanserin, 853
Conditioned stimulus, 859
cyclophosphamide
mice, female
T-cell antibody responses
unconditioned stimulus
Conditioned taste aversion
central nicotinic receptors, 235
discriminative stimulus, 235
methylnaltrexone, 687
morphine, 687
nicotine, 235
opiate aversive effects, 687
preexposure effects, 687
Conflict behavior, 471
alpha-adrenoceptors
biphasic effects
clonidine
Contextual fear, 209
chlordiazepoxide
nociception
shock controllability
Continuous administration, 535
amphetamine
circadian rhythm
locomotor behavior
stereotypy
Continuous infusion, 357
embryos, chicken
methadone
opioid dependence
osmotic mini-pumps
Corticosterone, 101
adrenalectomy
schedule-induced wheel running
Corticotropin-releasing hormone, 801
freezing behavior
intracerebroventricular administration
pain sensitivity
Crabs, 635
defensive response
morphine
naloxone
Cross-tolerance, 385
chlordiazepoxide
chronic intake
ethanol
ethanol tolerance
CS-UCS interval, 433
classical conditioning
d-lysergic acid diethylamide
reflex facilitation
Cyclazocine, 163
dissociation
naltrexone
nonopioid effects
opioid effects
[^{3}H]Cyclohexyladenosine, 169
chronic stress
hypothalamus
receptor ligand binding
Cyclophosphamide, 859
conditioned stimulus
mice, female
T-cell antibody responses
unconditioned stimulus

D_1/D_2 agonists, 457
dopamine
EEDQ
rotational behavior
selective protection
D1/D2 dopamine receptor stimulation, 189
SKF 38393
stereotyped behaviors
Daily running activity
desipramine
inescapable stress
long-term effects
Defensive burying, 1071
anxiolytics
buspirone
chlordiazepoxide
drug comparisons
shock-probe test
Defensive response, 635
crabs
morphine
naloxone
2-Deoxyglucose, 781
autoradiography
brain regional uptake
ethanol
strain differences
Desipramine
daily running activity, 21
ethanol intake, 1045
fluoxetine, 1045
food intake, 1045
inescapable stress, 21
long-term effects, 21
RO 15-4513, 1045
strain differences, 1045
water intake, 1045
Desmethylimipramine, 299
chronic administration
clorgyline
drinking
eating
Dexfenfluramine, 89
anorexia
ischymetric mechanisms
lipostatic mechanisms
metabolic chamber
Diazepam
adenosine receptor downregulation, 303
d-amphetamine, 853
behavioral/electrocorticographic comparisons, 479
brain, rat, 303
chronic administration, 303
conditioned place preference, 853
dogs, 945
drug interactions, 479, 853
flumazenil, 945
morphine, 853

oral absorption, 945
pentylenetetrazol, 479
rat pups, 479
ritanserin, 853
Differential effects, 397
approach response
electrical stimulation
escape response
intracerebral microinjection
lateral hypothalamus
morphine
Differential sensitivity, 183
ethanol antagonism
RO 15-4513
strain differences
Differential tolerance, 977
buprenorphine
diprenorphine
drug comparisons
food intake
heroin
monkeys
Dihydroergocristine, 961
learning and memory
rats, aged males
Diprenorphine, 977
buprenorphine
differential tolerance
drug comparisons
food intake
heroin
monkeys
Discrete brain regions, 795
biogenic amines
high performance liquid chromatography
Discriminative stimulus
central nicotinic receptors, 235
citalopram, 613
conditioned taste aversion, 235
drug comparisons, 613
drug interactions, 617
l-5-hydroxytryptophan, 613
LSD, 617
nicotine, 235
RO 4-46202, 613
serotonergic agonists, 617
serotonergic antagonists, 617
Dissociation, 163
cyclazocine
naltrexone
nonopioid effects
opioid effects
Dogs, 945
diazepam
flumazenil
oral absorption
l-Dopa, 585
chronic administration
haloperidol
rebound enhancement
self-stimulation
Dopamine
amphetamine, 641
amphetamine anorexia, 641
behavioral microanalysis, 641
D_1/D_2 agonists, 457
drug interactions, 641
EEDQ, 457
hyperactivity, 577
lateral hypothalamus, 365
median raphe nucleus, 577
morphine, 577
neonatal depletions, 365
rats, adult, 365
rotational behavior, 457
selective protection, 457
stimulation reward, 365
Dopamine D-1 receptors, 325
dopamine D-2 receptors
receptor density
receptor distribution
strain differences
Dopamine D-2 receptors, 325
dopamine D-1 receptors
receptor density
receptor distribution
strain differences
Dopamine innervation, 693
aversive effects
lesions, 6-OHDA
opiates
visceral cortex
Dopamine-mediated behavior, 463
drug comparisons
Dopamine receptors
catalepsy, 765
dose-dependent effects, 765
drug discrimination, 55
drug interactions, 55, 765
environment-specific conditioning, 525
ethanol, 55
LY17155, 765
quinpirole, 525
serotonin receptors, 55
Dopaminergic uptake blocker, 1077
circling behavior
morphine
Dorsal noradrenergic bundle, 835
learning
lesions, 6-hydroxydopamine
memory
Dorsomedial hypothalamic nucleus, 649
ad lib feeding
body weight restriction
food restriction
lesions, dorsomedial hypothalamic nucleus
Dose-dependent effects
acute effects, 737
apomorphine, 107
behavioral tolerance, 737
body temperature, 451
catalepsy, 765
cholecystokinin, 569
chronic effects, 737
chronic treatment, 451
cocaine, 737
complex operant behavior, 737
dopamine receptor, 765
drug interactions, 451, 765
LY17155, 765
monkeys, 737
8-OH-DPAT, 451
passive avoidance learning, 107
rate-decreasing effects, 569
schedule-controlled behavior, 569
Drinking
chronic administration, 299
clorgyline, 299
desmethylimipramine, 299
lateral hypothalamus, 917
sulpiride, 917
Drug
adinazolam, 73
N-allylnormetazocine, 493
alprazolam, 73, 511
α-amino-3-hydroxy-5-methyl isoxazole-4-propionate, 379
2-amino-5-phosphonovaleric acid, 529
amphetamine, 489, 535, 641, 871
d-amphetamine, 45, 309, 853, 1085, 1089, 1093
dl-amphetamine, 899
(−)-anabasine, 255
apomorhpine, 77, 107, 143, 189, 457, 463, 641, 683, 753, 889
arecoline, 1093
atropine, 625
baclofen, 995
bicuculline, 337, 995
bremazocine, 817
4-bromo-2,5-dimethoxyphenethylamine, 597
buprenorphine, 195, 977
buspirone, 55, 723, 775, 1071
γ-butyrolactone, 45
caffeine, 707, 809
cannabidiol, 675
cannabinol, 675
carbachol, 129
carbamazepine, 409
cathinone, 755, 1089
CGS 10746B, 1089
chlordiazepoxide, 209, 331, 515, 775, 1071
chlorpromazine, 603
7-(2-chloroethyl)-theophylline, 155
citalopram, 613
clenbuterol, 417
clomipramine, 451
clonazepam, 749
clonidine, 77, 451, 471, 925
clorgyline, 299, 347, 451
clozapine, 603
cocaine, 1, 243, 589, 737, 1089
codeine, 115
corticosterone, 101
(dl)-cyclazocine, 163
(l)-cyclazocine, 163
cyclophosphamide, 859
(−)-cytisine, 255
desipramine, 21, 1045
desmethylimipramine, 137, 299
dexfenfluramine, 89
diazepam, 115, 303, 331, 479, 679, 755, 853, 945, 995
dihydroergocristine, 961
5,6-dihydroxytryptamine, 319
dilezep, 155
diprenorphine, 977
DOM, 617
l-dopa, 77, 585
dopamine, 365, 641, 693
DPS-4, 137
enalapril, 823
estazolam, 73
ethanol, 55, 155, 177, 501, 769, 781, 867, 933
ethyl β-carboline-3-carboxylate, 243
ethylketocyclazocine, 817
d-fenfluramine, 715
fentanyl, 879
FG 7142, 351, 701
flumazenil, 945
fluoxetine, 77, 823, 1045

α-fluphenthixol, 693
GBR-13069, 1077
gepirone, 723
haloperidol, 55, 309, 451, 585, 589, 603, 683
heroin, 443, 977, 983
8-hydroxy-2-(di-n-propylamino) tetralin, 723
3-hydroxykynurenine, 665
l-5-hydroxytryptophan, 613
imipramine, 1, 451, 775, 889
isofloxythepin, 1081
isoproterenol, 417
ketamine, 421
kynurenic acid, 529
(−)-lobeline, 255
[^{3}H]lormetazepam, 679
loxapine, 603
LSD, 613, 617
LY 171555, 55, 453
d-lysergic acid diethylamine, 427, 433
marijuana, 539
MDMT, 617
mecamylamine, 149
medroxyprogesterone acetate, 829
5-MeODMT, 55, 679
meprobamate, 775
metergoline, 451
methadone, 357
methaqualone, 483
methiotepin, 451
5-methoxy DMT, 77
5-methoxytryptamine, 847
methylnaltrexone, 687
methylphenidate, 879
MK-801, 205
molindone, 603
morphine, 13, 123, 243, 319, 397, 569, 577, 635, 687, 693, 755, 775, 789, 853, 905, 1021, 1051, 1077
MR 2266, 817
nadolol, 417
naloxone, 13, 45, 451, 543, 589, 635, 791, 905, 967, 1077
naltrexone, 115, 163, 569, 817
nicotine, 119, 149, 199, 217, 227, 235, 243, 249, 269, 403, 879, 1059, 1065
(−)-nicotine, 255
(+)-nicotine, 255
nisoxetine, 1085
nitrous oxide, 83
nomifensine, 1077
^{3}H-norepinephrine, 391
8-OH-DPAT, 55, 451, 613, 617
parachlorophenylalanine, 847
pentobarbital, 995
pentylenetetrazol, 479
phencyclidine, 31, 205, 371, 493, 1035
l-phenylcyclohexane, 1035
phenobarbital, 879, 995
phenoxybenzamine, 451
phenylephrine, 77
picrotoxin, 995
pimozide, 641
pindolol, 451
pirenperone, 37, 55, 613, 617
pirenzepine, 519
pizotifen, 55
pizotyline, 613, 617
propanolol, 451
(−)propranolol, 55
quinpirole, 189, 457, 525
quinuclidinyl benzilate, 31
quipazine, 37, 55
ritanserin, 451, 853
RO 4-4602, 613
RO 5-4864, 749
RO 15-1788, 331
RO 15-3505, 701
RO 15-4513, 183, 501, 701, 867, 1045
RU-24969, 617
salbutamol, 77
SCH 23390, 463, 683, 765
scopolamine, 119, 205, 295, 625, 949, 1093
semicarbazide, 337
SKF 38393, 55, 189, 457, 463
SMS 201-995, 295
strychnine, 995
sulpiride, 917
(−)-sulpiride, 765
tamoxifen, 829
TFMPP, 55, 613, 617
theophylline, 155
thioridazine, 641
THIP, 995
triazolam, 73
U50488H, 755
YM 09151-2, 463
zolantidine, 791

Drug-admixed food method, 483
  methaqualone
  physical dependence
  sex differences

Drug comparisons
  anxiolytics, 1071
  buprenorphine, 977
  buspirone, 723, 1071
  central benzodiazepine agonist, 749
  chlordiazepoxide, 1071
  citalopram, 613
  clonazapam, 749
  clozapine, 603
  defensive burying, 1071
  differential tolerance, 977
  discriminative stimulus, 613
  dopamine-mediated behavior, 463
  fixed-consecutive-number responding, 603
  food intake, 977
  gepirone, 723
  heroin, 977
  8-hydroxy-2-(di-n-propyl-amino)tetralin, 723
  l-5-hydroxytryptophan, 613
  monkeys, 977
  NaCl intake, 749
  peripheral benzodiazepine agonist, 749
  pigeons, 723
  RO 4-46202, 613
  RO 5-4864, 749
  shock-probe test, 1071
  unpunished responding, 723

Drug discrimination
  d-amphetamine, 1085, 1089
  β-carbolines, 351
  CGS 10746B, 1089
  drug interactions, 55
  dopamine receptors, 55
  ethanol, 55
  FG 7142, 351
  footshock, 351
  nisoxetine, 1085
  novel environment, 351
  serotonin receptors, 55

Drug interactions
  amphetamine, 641
  d-amphetamine, 45, 853
  amphetamine anorexia, 641
  anxiety, 701
  behavioral/electrocorticographic comparisons, 479
  behavioral microanalysis, 641
  benzodiazepine receptors, 701
  body temperature, 451, 675
  γ-butyrolactone, 45
  cannabidiol, 675
  cannabinol, 675
  catalepsy, 765
  catecholamines, 589
  chemoconvulsants, 995
  chronic treatment, 451
  conditioned place preference, 853
  diazepam, 479, 853
  discriminative stimulus, 617
  dopamine, 641
  dopamine receptor, 55, 765
  dose-dependent effects, 451, 765
  drug discrimination, 55
  endogenous opioids, 589
  ethanol, 55, 501, 701, 867
  GABAergic drugs, 995
  GABAergic system, 501
  lever pressing, 45
  light/dark choice paradigm, 867
  locus coeruleus, 13
  locus coeruleus stimulation, 13
  lordosis, 37
  LSD, 617
  LY17155, 765
  alpha-melanocyte stimulating hormone, 37
  molecular interactions, 501
  monkeys, 13
  morphine, 13, 853
  morphine withdrawal, 13
  naloxone, 13, 45
  8-OH-DPAT, 451
  open-field activity, 675
  pentobarbital, 995
  pentylenetetrazol, 479
  phencyclidine, 1035
  phenobarbital, 995
  l-phenylcyclohexane, 1035
  plus-maze test, 701
  rat pups, 479
  ritanserin, 853
  RO 15-4513, 501, 867
  self-stimulation reward, 589
  serotonin, 37
  serotonergic agonists, 617
  serotonergic antagonists, 617
  serotonin receptors, 55
  staircase test, 867
  ventral tegmental area, 589

Drug self-administration, 227
  human studies
  intravenous administration
  nicotine
  reinforcing effects

Drugs of abuse, 597
  4-bromo-2,5-dimethoxyphen-ethylamine

Eating
  chronic administration, 299
  clorgyline, 299
  desmethylimipramine, 299
  lateral hypothalamus, 917

sulpiride, 917
EEDQ, 457
D_1/D_2 agonists
dopamine
rotational behavior
selective protection
EEG power spectra, 489
amphetamine
motor activity
Eight-arm radial maze, 119
nicotine
scopolamine
Electrical stimulation, 397
approach response
differential effects
escape response
intracerebral microinjection
lateral hypothalamus
morphine
Electroencephalogram, 149
human studies, males
mecamylamine
nicotine
nicotine gum
Embryos, chicken, 357
continuous infusion
methadone
opioid dependence
osmotic mini-pump
Endogenous opioids, 589
catecholamines
drug interactions
self-stimulation reward
ventral tegmental area
β-Endorphin levels, 933
ethanol
ethanol withdrawal
pituitary
Environment-specific conditioning, 525
dopamine receptor
quinpirole
Escape, 957
frogs
skin mucus
tardive dyskinesia
Escape response, 397
approach response
differential effects
electrical stimulation
intracerebral injection
lateral hypothalamus
morphine
Estrous cycle, 563
monoamines
postpartum period
pregnancy
Ethanol
acute administration, 769
adenosine, 155
anxiety, 701
autoradiography, 781
benzodiazepine receptors, 701
brain regional uptake, 781
cerebellum, 155
chlordiazepoxide, 385
chronic intake, 385
cross-tolerance, 385
2-deoxyglucose, 781
dopamine receptors, 55
drug discrimination, 55
drug interactions, 55, 501, 701, 867
β-endorphin levels, 933
ethanol tolerance, 385
ethanol withdrawal, 933
GABAergic system, 501
hippocampus, 177
light/dark choice paradigm, 867
MHPG-SO_4, 769
molecular interactions, 501
motor incoordination, 155
noradrenaline metabolism, 769
pituitary, 933
plus-maze test, 701
rhythmic slow activity, 177
RO 15-4513, 501, 867
serotonin receptors, 55
spontaneous motor activity inhibition, 155
staircase test, 867
strain differences, 177, 769, 781
Ethanol antagonism, 183
differential sensitivity
RO 15-4513
strain differences
Ethanol intake, 1045
desipramine
fluoxetine
food intake
RO 15-4513
strain differences
water intake
Ethanol tolerance, 385
chlordiazepoxide
chronic intake
cross-tolerance
ethanol
Ethanol withdrawal, 933
β-endorphin levels
ethanol
pituitary
Ethylketocyclazocine, 817
analgesia
bremazocine
neonatal administration
Excitatory amino acid antagonists, 529
ingestive behaviors
median raphe nucleus

Feeding behavior, 925
clonidine
d-Fenfluramine, 715
serotonin metabolism, brain
uptake inhibition
FG 7142, 351
β-carbolines
drug discrimination
footshock
novel environment
Fixed-consecutive-number responding, 603
clozapine
drug comparisons
Flash evoked potentials, 421
ketamine
Flight behavior, 337
bicuculline
microinjection
rats, detelencephalated
semicarbazide
Flumazenil, 945
diazepam
dogs
oral absorption
Fluoxetine, 1045
desipramine
ethanol intake
food intake
RO 15-4513
strain differences
water intake
Food intake
buprenorphine, 977
desipramine, 1045
differential tolerance, 977
diprenorphine, 977
drug comparisons, 977
ethanol intake, 1045
fluoxetine, 1045
heroin, 977
intravenous self-administration, 1051
lesions, 6-hydroxydopamine, 1051
monkeys, 977
morphine, 1051
nucleus accumbens, 1051
RO 15-4513
strain differences, 1045
water intake, 1045
Food restriction, 649
ad lib feeding
body weight restriction
dorsomedial hypothalamic nucleus
lesions, dorsomedial hypothalamic nucleus
Footshock, 351
β-carbolines
drug discrimination
FG 7142
novel environment
Four-drug discrimination, 879
identical levers
response manipulandum
Freezing behavior, 801
corticotropin-releasing hormone
intracerebroventricular administration
pain sensitivity
Frogs, 957
escape
skin mucus
tardive dyskinesia
Frontal cortex, 129
anatomical analysis
carbachol
motor seizures
Functional neuroanatomy, 983
auditory stimulus
heroin

GABA agonists, 657
lateral hypothalamus
reward effect
self-stimulation
GABAergic drugs, 995
chemoconvulsants
drug interactions
pentobarbital
phenobarbital
GABAergic system, 501
drug interactions
ethanol
molecular interactions
RO 15-4513
GABA-gated chloride channels, 911
asymmetrical activation
cerebral cortex
Genetic analysis, 143
apomorphine
climbing behavior
locomotor behavior
Genetic breeding, 343

angiotensins
blood pressure responsiveness
intracarotid infusion
Genetic differences, 1059
nicotine
plasma corticosterone levels
Genetic influence, 269
acute response
nicotine
nicotine tolerance
Gepirone, 723
buspirone
drug comparisons
8-hydroxy-2-(di-n-propyl-amino)tetralin
pigeons
unpunished responding

Haloperidol
apomorphine, 683
body temperature, 683
chronic administration, 585
l-dopa, 585
rebound enhancement, 585
SCH 23390, 683
self-stimulation, 585
Heart, 1015
kidney
peripheral benzodiazepine receptors
[^{3}H] RO 5-4864 binding
stress
Heroin
antagonist treatment, 443
auditory stimulus, 983
buprenorphine, 977
differential tolerance, 977
diprenorphine, 977
drug comparisons, 977
food intake, 977
functional neuroanatomy, 983
intravenous self-administration, 443
monkeys, 977
nucleus accumbens, 443
periaqueductal grey, 443
High performance liquid chromatography, 795
biogenic amines
discrete brain regions
Hippocampus
conditioned place preference, 787
ethanol, 177
morphine, 787
rhythmic slow activity, 177
strain differences, 177
Hormone
alphaxalone, 729
progesterone, 729
H_2-receptor, 791
adrenalectomy
analgesia, stress-induced
hypophysectomy
Human studies
drug self-administration, 227
intravenous administration, 227
marijuana smoke, 895
nicotine, 217, 227
nitrous oxide, 83
pharmacologic determinants, 221
pharmacological effects, 217
reinforcing effects, 227
salivary cotinine, 895
serum cotinine, 895
state-dependent memory, 83
tobacco dependence, 217
tobacco self-administration, 221
tobacco smoke, 895
Human studies, males
electroencephalogram, 149
marijuana, 539
mecamylamine, 149
metabolic data, 249
naloxone, 967
nicotine, 149, 249
nicotine gum, 149
nicotine metabolism, 249
prolactin response, 967
psychopharmacology, 967
small groups, 539
social behavior, 539
Hunger-mimetic model, 515
benzodiazepines
chlordiazepoxide
hyperphagia
8-Hydroxy-2-(di-n-propyl-amino)tetralin, 723
buspirone
drug comparisons
gepirone
pigeons
unpunished responding
3-Hydroxykynurenine, 665
benzodiazepine receptor binding affinity
neonatal deficiency
seizures
vitamin B-6
5-Hydroxytryptamine receptors, 347
circadian studies
clorgyline
l-5-Hydroxytryptophan, 613
citalopram
discriminative stimulus
drug comparisons
RO 4-46202
Hyperactivity, 577
dopamine
median raphe nucleus
morphine
Hyperlocomotion, 309
amphetamine
cholecystokinin-octapeptide
intra-accumbens injections
intracerebroventricular injection
route of administration
stereotypy
Hypermotility, 379
α-amino-3-hydroxy-5-methylisox-azole-4-propionate
nucleus accumbens
quisqualic acid receptors
Hyperphagia, 515
benzodiazepines
chlordiazepoxide
hunger-mimetic model
Hypophysectomy, 791
adrenalectomy
analgesia, stress-induced
H_2-receptor
Hypotension, 65
antinociception
bradycardia
intrathecal antagonists
intravenous administration
[D-Ala^2]-methionine enkephalinamide
Hypothalamus, 169
chronic stress
[^{3}H]cyclohexyladenosine receptor ligand binding
Hypothermia, 941
brain, rat
thyrotropin-releasing hormone

Identical levers, 879
four-drug discrimination
response manipulandum
Imipramine
cocaine, 1
interactive effects, 1
long-term treatment, 889
place preference, apomorphine-induced, 889
place preference, food-induced
self stimulation, 1
short-term treatment, 889
train-duration thresholds, 1
Immobility response, 625
atropine
chickens
scopolamine
strain differences
Inescapable stress, 21
daily running activity
desipramine
long-term effects
Ingestive behaviors, 529
excitatory amino acid antagonists
median raphe nucleus
Interactive effects, 1
cocaine
imipramine
self-stimulation
train-duration thresholds
Intestinal inhibition, 319
analgesia
morphine
supraspinal cerebral areas
Intra-accumbens injection, 309
amphetamine
cholecystokinin-octapeptide
hyperlocomotion
intracerebroventricular injection
route of administration
stereotypy
Intracarotid infusion, 343
angiotensins
blood pressure responsiveness
genetic breeding
Intracerebral microinjection, 397
approach response
differential effects
electrical stimulation
escape response
lateral hypothalamus
morphine
Intracerebroventricular administration, 801
corticotropin-releasing hormone
freezing behavior
pain sensitivity
Intracerebroventricular injection, 309
amphetamine
cholecystokinin-octapeptide
hyperlocomotion
intra-accumbens injection
route of administration
stereotypy

Intrathecal antagonists, 65
antinociception
bradycardia
hypotension
intravenous administration
[D-Ala²]-methionine enkephalinamide
Intravenous administration
antinociception, 65
bradycardia, 65
drug self-administration, 227
human studies, 227
hypotension, 65
intrathecal antagonists, 65
[D-Ala²]-methionine enkephalinamide
monkeys, 243
reinforcing effects, 227
Intravenous self-administration
antagonist treatment, 443
food intake, 1051
heroin, 443
lesions, 6-hydroxydopamine, 1051
morphine, 1051
nucleus accumbens, 443, 1051
periaqueductal grey, 443
Inverse benzodiazepine agonists, 5
in vitro
in vivo
neuropharmacology
rabbits
Investigatory behavior, 417
clenbuterol
locomotor activity
peripheral mediation
In vitro, 5
inverse benzodiazepine agonists
in vivo
neuropharmacology
rabbits
In vitro autoradiography, 679
benzodiazepine binding sites
substantia innominata
In vivo
inverse benzodiazepine agonists, 5
in vitro, 5
neuropharmacology, 5
parametric studies, 31
phencyclidine, 31
quinuclidinyl benzilate, 31
rabbits, 5
Ionizing radiation, 1007
schedule-controlled performance
sublethal doses
Ischymetric mechanisms, 89
anorexia
dexfenfluramine
lipostatic mechanisms
metabolic chamber
Isofloxythepin, 1081
isofloxythepin enantiomers
postdecapitation convulsions
prolactin secretion
Isofloxythepin enantiomers, 1081
isofloxythepin
postdecapitation convulsions
prolactin secretion

Jumping, naloxone-induced, 905
analgesia, morphine-induced
morphine
naloxone
restraint

Ketamine, 421
flash evoked potentials
Kidney, 1015
heart
peripheral benzodiazepine receptors
[³H] RO 5-4864 binding
stress

Latent inhibition disruption, 871
acute administration
amphetamine
Lateral hypothalamus
approach response, 397
differential effects, 397
dopamine, 365
drinking, 917
eating, 917
electrical stimulation, 397
escape response, 397
GABA agonists, 657
intracerebral microinjection, 397
morphine, 397
neonatal depletions, 365
rats, adult, 365
reward effect, 657
self-stimulation, 657
stimulation reward, 365
sulpiride, 917
Learning, 835
dorsal noradrenergic bundle
lesions, 6-hydroxydopamine
memory
Learning and memory, 961
dihydroergocristine
rats, aged males
Lesions, dorsomedial hypothalamic nucleus, 649
ad lib feeding
body weight restriction
dorsomedial hypothalamic nucleus
food restriction
Lesions, 6-hydroxydopamine
aversive effects, 693
dopamine innervation, 693
dorsal noradrenergic bundle, 835
food intake, 1051
intravenous self-administration, 1051
learning, 835
memory, 835
morphine, 1051
nucleus accumbens, 1051
opiates, 693
visceral cortex, 693
Lever pressing, 45
d-amphetamine
γ-butyrolactone
drug interactions
naloxone
Light/dark choice paradigm, 867
drug interactions
ethanol
RO 15-4513
staircase test
Lipostatic mechanisms, 89
anorexia
dexfenfluramine
ischymetric mechanisms
metabolic chamber
Locomotor behavior
aggressive behavior, 729
alphaxalone, 729
amphetamine, 535
apomorphine, 143
circadian rhythm, 535
clenbuterol, 417
climbing behavior, 143
comparative effects, 729
continuous administration, 535
genetic analysis, 143
investigatory behavior, 417
peripheral mediation, 417
progesterone, 729
reproductive behavior, 729
stereotypy, 535
Locus coeruleus, 13
drug interactions
locus coeruleus stimulation
monkeys
morphine
morphine withdrawal
naloxone
Locus coeruleus stimulation, 13
drug interactions
locus coeruleus
monkeys
morphine
morphine withdrawal
naloxone
Long-term effects, 21
daily running activity
desipramine
inescapable stress
Long-term treatment, 889
imipramine
place preference, apomorphine-induced
place preference, food-induced
short-term treatment
Lordosis, 37
drug interactions
alpha-melanocyte stimulating hormone
serotonin
Low-dose administration, 511
alprazolam
motor activity
LSD, 617
discriminative stimulus
drug interactions
serotonergic agonists
serotonergic antagonists
LY17155, 765
catalepsy
dopamine receptor
dose-dependent effects
drug interactions
d-Lysergic acid diethylamide
classical conditioning, 433
classical trace conditioning, 427
CS-UCS interval, 433
reflex facilitation, 433

Marijuana, 539
human studies, males
small groups
social behavior
Marijuana smoke, 895
human studies
salivary cotinine
serum cotinine
tobacco smoke
Maternal stress, 669
5-MeODMT
open-field activity

postnatal factors
prenatal factors
Mecamylamine, 149
electroencephalogram
human studies, males
nicotine
nicotine gum
Median raphe nucleus
dopamine, 577
excitatory amino acid antagonists, 529
hyperactivity, 577
ingestive behaviors, 529
morphine, 577
Medroxyprogesterone acetate, 829
aggressive behavior
mice, male
tamoxifen
alpha-Melanoctye stimulating hormone, 37
drug interactions
lordosis
serotonin
Memory, 835
dorsal noradrenergic bundle
learning
lesions, 6-hydroxydopamine
Memory retrieval, 77
active avoidance
aminergic neurotransmitter systems
pharmacological stimulation
5-MeODMT, 669
maternal stress
open-field activity
postnatal factors
prenatal factors
Metabolic chamber, 89
anorexia
dexfenfluramine
ischymetric mechanisms
lipostatic mechanisms
Metabolic data, 249
human studies, males
nicotine
nicotine metabolism
Methadone, 357
continuous infusion
embryos, chicken
opioid dependence
osmotic mini-pumps
Methaqualone, 483
drug-admixed food method
physical dependence
sex differences
[D-Ala^2]-Methionine enkephalinamide, 65
antinociception
bradycardia
hypotension
intrathecal antagonists
intravenous administration
Method
autoradiography, 325, 781
drug-admixed food method, 483
gas chromatography-mass spectrometry, 249
high performance liquid chromatography, 795
Montgomery's conflict test, 471
Vogel's conflict test, 471
5-Methoxytryptamine, 847
behavioral effects
parachlorophenylalanine
prenatal exposure
serotonin uptake
Methylnaltrexone, 687
conditioned taste aversion
morphine
opiate aversive effects
preexposure effects
Methylxanthines, 707
adenosine receptors
autoradiography
strain differences
MHPG-SO_4, 769
acute administration
ethanol
noradrenaline metabolism
strain differences
Mice, female, 859
conditioned stimulus
cyclophosphamide
T-cell antibody responses
unconditioned stimulus
Mice, male, 829
aggressive behavior
medroxyprogesterone acetate
tamoxifen
Microinjection, 337
bicuculline
flight behavior
rats, detelencephalated
semicarbazide
Midbrain periaqueductal gray, 409
aggression
carbamazepine
cats
MK-801, 205
amnesia
Molecular interactions, 501
drug interactions
ethanol
GABAergic system
RO 15-4513
Monkeys
acute effects, 737
behavioral tolerance, 737
buprenorphine, 977
chronic effects, 737
cocaine, 737
complex operant behavior, 737
differential tolerance, 977
diprenorphine, 977
dose-dependent effects, 737
drug comparisons, 977
drug interactions, 13
food intake, 977
heroin, 977
intravenous administration, 243
locus coeruleus, 13
locus coeruleus stimulation, 13
morphine, 13
morphine withdrawal, 13
naloxone, 13
nicotine, 243
Monoamines, 563
estrous cycle
postpartum period
pregnancy
Morphine
d-amphetamine, 853
analgesia, 123, 319
analgesia, morphine-induced, 905
approach response, 397
circling behavior, 1077
conditioned place preference, 787, 853
conditioned taste aversion, 687
crabs, 635
defensive response, 635
diazepam, 853
differential effects, 397
dopamine, 577
dopaminergic uptake blocker, 1077
drug interactions, 13, 853
electrical stimulation, 397
escape response, 397
food intake, 1051
hippocampus, 787
hyperactivity, 77
intestinal inhibition, 319
intracerebral microinjection, 397
intravenous self-administration, 1051
jumping, naloxone-induced
lateral hypothalamus, 397
lesions, 6-hydroxydopamine, 1051
locus coeruleus, 13
locus coeruleus stimulation, 13
median raphe nucleus, 577
methylnaltrexone, 687
monkeys, 13
morphine withdrawal, 13
naloxone, 13, 635, 905
nucleus accumbens, 1051
opiate aversive effects, 687
preexposure effects, 687
prenatal stress, 123
restraint, 905
ritanserin, 853
sex differences, 123
supraspinal cerebral areas, 319
Morphine withdrawal, 13
drug interactions
locus coeruleus
locus coeruleus stimulation
monkeys
morphine
naloxone
Morris Water Maze, 519
pirenzepine
spatial learning
Motor activity
alprazolam, 511
amphetamine, 489
EEG power spectra, 489
low-dose administration, 511
Motor development, 199
activity meter
nicotine
prenatal changes
Motor incoordination, 155
adenosine
cerebellum
ethanol
spontaneous motor activity inhibition
Motor seizures, 129
anatomical analysis
carbachol
frontal cortex

NaCl intake, 749
central benzodiazepine agonist
clonazepam
drug comparisons
peripheral benzodiazepine agonist
RO 5-4864
Naloxone
d-amphetamine, 45
analgesia, morphine-induced, 905
γ-butyrolactone, 45

cats, 543
crabs, 635
defensive response, 635
drug interactions, 13, 45
human studies, males, 967
jumping, naloxone-induced, 905
lever pressing, 45
locus coeruleus, 13
locus coeruleus stimulation, 13
monkeys, 13
morphine, 13, 635, 905
morphine withdrawal, 13
penile erection, 543
prolactin response, 967
psychopharmacology, 967
restraint, 905
Naltrexone, 163
cyclazocine
dissociation
nonopioid effects
opioid effects
Neonatal administration, 817
analgesia
bremazocine
ethylketocyclazocine
Neonatal deficiency, 665
benzodiazepine receptor binding affinity
3-hydroxykynurenine
seizures
vitamin B-6
Neonatal depletions, 365
dopamine
lateral hypothalamus
rats, adult
stimulation reward
Neuropharmacology, 5
inverse benzodiazepine agonists, 5
in vitro
in vivo
rabbits
Nicotine
activity meter, 199
acute pretreatment, 1065
acute response, 269
carbamate esters, 403
central nicotinic receptors, 235
conditioned taste aversion, 235
discriminative stimulus, 235
drug self-administration, 227
eight-arm radial maze
electroencephalogram, 149
genetic differences, 1059
genetic influence, 269
human studies, 217, 227
human studies, males, 149, 249
intravenous administrations, 227, 243
mecamylamine, 149
metabolic data, 249
monkeys, 243
motor development, 199
nicotine agonists, 403
nicotine antagonists, 403
nicotine gum, 149
nicotine metabolism, 249
nicotine tolerance, 269
pharmacological effects, 217
plasma corticosterone levels, 1059, 1065
prenatal changes, 199
reinforcing effects, 227
scopolamine, 119
strain differences, 1065
structure-activity studies, 403
tobacco dependence, 217
Nicotine agonists, 403
carbamate esters
nicotine
nicotine antagonists
structure-activity studies
Nicotine antagonists, 403
carbamate esters
nicotine
nicotine agonists
structure-activity studies
Nicotine gum
electroencephalogram, 149
human studies, males, 149
mecamylamine, 149
nicotine, 149
pharmacological treatment, 279
tobacco dependence, 279
Nicotine metabolism, 249
human studies, males
metabolic data
nicotine
Nicotine tolerance, 269
acute response
genetic influence
nicotine
Nicotinic ligands, 255
binding characteristics
pharmacologic analysis
Nisoxetine, 1085
d-amphetamine
drug discrimination
Nitrous oxide, 83
human studies
state-dependent memory
Nociception, 209
chlordiazepoxide
contextual fear
shock controllability
Nonopioid effects, 163
cyclazocine
dissociation
naltrexone
opioid effects
Noradrenaline metabolism, 769
acute administration
ethanol
MHPG-SO_4
strain differences
Norepinephrine, 137
cerebral depletion
conditioned avoidance responding
^{3}H-Norepinephrine uptake, 391
(1–24)adrenocorticotropic hormone
atria, rat
Novel environment, 351
β-carbolines
drug discrimination
FG 7142
footshock
Nucleus accumbens
α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate, 379
antagonist treatment, 443
food intake, 1051
heroin, 443
hypermotility, 379
intravenous self-administration, 443, 1051
lesions, 5-hydroxydopamine, 1051
morphine, 1051
periaqueductal grey, 443
quisqualic acid receptors, 379

8-OH-DPAT, 451
body temperature
chronic treatment
dose-dependent effects
drug interactions
Open-field activity
body temperature, 675
cannabidiol, 675
cannabinol, 675
drug interactions, 675
maternal stress, 669
5-MeODMT, 669
postnatal factors, 669
prenatal factors, 669
Opiate aversive effects, 687
conditioned taste aversion
methylnaltrexone
morphine
preexposure effects
Opiate mechanisms, 755
amphetamine
anorectic effects
tolerance development
U50488H
Opiates, 693
aversive effects
dopamine innervation
lesions, 6-OHDA
visceral cortex
Opioid dependence, 357
continuous infusion
embryos, chicken
methadone
osmotic minipumps
Opioid effects, 163
cyclazocine
dissociation
naltrexone
nonopioid effects
Opioids, 1021
rat, male
sexual behavior
Oral absorption, 945
diazepam
dogs
flumazenil
Oral self-administration, 493
N-allylnormetazocine
phencyclidine
rhesus monkeys
withdrawal
Osmotic mini-pumps, 357
continuous infusion
embryos, chicken
methadone
opioid dependence

Pain sensitivity, 801
corticotropin-releasing hormone
freezing behavior
intracerebroventricular administration
Parachlorophenylalanine, 847
behavioral effects
5-methoxytryptamine
prenatal exposure
serotonin uptake
Paradoxical sleep suppression, 295
scopolamine

SMS 201-995
Parametric studies, 31
in vivo
phencyclidine
quinuclidinyl benzilate
Passive avoidance learning, 107
apomorphine
dose-dependent effects
Penile erection, 543
cats
naloxone
Pentobarbital, 995
chemoconvulsants
drug interactions
GABAergic drugs
phenobarbital
Pentylenetetrazol, 479
behavioral/electrocorticographic comparisons
diazepam
drug interactions
rat pups
Peptides
(1–24)adrenocorticotropic hormone, 391
D-Ala²-Met⁵-enkephalinamide, 1021
[D-Ala²]-methionine enkephalinamide, 65
angiotensin II, 343
angiotensin III, 343
caerulein, 957
cholecystokinin, 569, 957
cholecystokinin-octapeptide, 309
corticotropin-releasing hormone, 801
alpha-melanocyte stimulating hormone, 37
serotonin, 37, 957
thyrotropin-releasing hormone, 73, 941, 957
xenopsin, 957
Periaqueductal grey, 443
antagonist treatment
heroin
intravenous self-administration
nucleus accumbens
Peripheral benzodiazepine agonist, 749
central benzodiazepine agonist
clonazepam
drug comparisons
NaCl intake
RO 5-4864
Peripheral benzodiazepine receptors, 1051
heart
kidney
[³H] RO 5-4864 binding
stress
Pentobarbital, 995
chemoconvulsants
drug interactions
GABAergic drugs
phenobarbital
Peripheral mediation, 417
clenbuterol
investigatory behavior
locomotor activity
Pharmacologic analysis, 255
binding characteristics
nicotinic ligands
Pharmacologic determinants, 221
human studies
tobacco self-administration
Pharmacological stimulation
active avoidance, 77
aminergic neurotransmitter systems, 77
human studies, 217
memory retrieval, 77
nicotine, 217
nicotine gum, 279
tobacco dependence, 217, 279
Phencyclidine
N-allylnormetazocine, 493
biodisposition, 371
charcoal, 371
drug interactions, 1035
in vivo, 31
oral self-administration, 493
parametric studies, 31
l-phenylcyclohexane, 1035
quinuclidinyl benzilate, 31
rhesus monkeys, 493
withdrawal, 493
Phenobarbital, 995
chemoconvulsants
drug interactions
GABAergic drugs
pentobarbital
l-Phenylcyclohexane, 1035
drug interactions
phencyclidine
Physical dependence, 483
drug-admixed food method
methaqualone
sex differences
Pigeons, 723
buspirone
drug comparisons
gepirone
8-hydroxy-2-(di-n-propyl-amino)tetralin
unpunished responding
Pirenzepine, 519
Morris Water Maze
spatial learning
Pituitary, 933
β-endorphin levels
ethanol
ethanol withdrawal
Place preference, apomorphine-induced, 889
imipramine
long-term treatment
place preference, food-induced
short-term treatment
Place preference, food-induced, 889
imipramine
long-term treatment
place preference, apomorphine-induced
short-term treatment
Plasma corticosterone levels
acute pretreatment, 1065
genetic differences, 1059
nicotine, 1059, 1065
strain differences, 1065
Plus maze test, 701
anxiety
benzodiazepine receptors
drug interactions
ethanol
Postdecapitation convulsions
benzodiazepines, 1001
isofloxythepin, 1081
isofloxythepin enantiomers, 1081
prolactin secretion, 1081
tonic component, 1001
Postnatal factors, 669
maternal stress
5-MeODMT
open-field activity
prenatal factors
Postpartum period, 563
estrous cycle
monoamines
pregnancy
Preexposure effects, 687
conditioned taste aversion
methylnaltrexone
morphine
opiate aversive effects
Pregnancy, 563
estrous cycle
monoamines
postpartum period
Prenatal changes, 199
activity meter
motor development
nicotine
Prenatal exposure, 847
behavioral effects
5-methoxytryptamine
parachlorophenylalanine
serotonin uptake
Prenatal factors, 669
maternal stress
5-MeODMT
open-field activity
postnatal factors
Prenatal stress, 123
analgesia
morphine
sex differences
Proconvulsant effects, 331
anxiogenic effects
benzodiazepine receptors
brain, rat
N-butyl β carboline-3-carboxylate
Progesterone, 729
aggressive behavior
alphaxalone
comparative effects
locomotor behavior
reproductive behavior
Prolactin response, 967
human studies, males
naloxone
psychopharmacology
Prolactin secretion, 1081
isofloxythepin
isofloxythepin enantiomers
postdecapitation convulsions
Psychopharmacology, 967
human studies, males
naloxone
prolactin response
Punished responding, 753
apomorphine
unpunished responding

Quinpirole, 525
dopamine receptor
environment-specific conditioning
Quinuclidinyl benzilate, 31
in vivo
parametric studies
phencyclidine

Quisqualic acid receptors, 379
α-amino-3-hydroxy-5-methylisoxazole-4-propionate
hypermotility
nucleus accumbens

Rabbits, 5
inverse benzodiazepine agonists
in vitro
in vivo
neuropharmacology
Rat, adult, 365
dopamine
lateral hypothalamus
neonatal depletions
stimulation reward
Rat, aged males, 961
dihydroergocristine
learning and memory
Rat, detelencephalated, 337
bicuculline
flight behavior
microinjection
semicarbazide
Rat, male, 1021
opioids
sexual behavior
Rat pups, 479
behavioral/electrocorticographic comparisons
diazepam
drug interactions
pentylenetetrazol
Rat/rabbit comparisons, 115
analepsis
codeine
Rate-decreasing effects, 569
cholecystokinin
dose-dependent effects
schedule-controlled behavior
Rebound enhancement, 585
chronic administration
l-dopa
haloperidol
self-stimulation
Receptor density, 325
dopamine D-1 receptors
dopamine D-2 receptors
receptor distribution
strain differences
Receptor distribution, 325
dopamine D-1 receptors
dopamine D-2 receptors
receptor density
strain differences
Receptor ligand binding, 169
chronic stress
[3H]cyclohexyladenosine
hypothalamus
Reflex facilitation, 433
classical conditioning
CS-UCS interval
d-lysergic acid diethylamide
Reinforcing effects, 227
drug self-administration
human studies
intravenous administration
nicotine
Reinforcing properties, 195
brain-stimulation reward
buprenorphine
reward threshold
Renin-angiotensin system, 823
alcohol intake
serotonin uptake inhibition
Reproductive behavior, 729
aggressive behavior
alphaxalone
comparative effects
locomotor behavior
progesterone
Response manipulandum, 879
four-drug discrimination
identical levers
Restraint, 905
analgesia, morphine-induced
jumping, naloxone-induced
morphine
naloxone
Retention, 949
acquisition
scopolamine
T-maze, 14-unit
Retrieval, 1093
amnesia
scopolamine
Reward effect, 657
GABA agonists
lateral hypothalamus
self-stimulation
Reward threshold, 195
brain-stimulation reward
buprenorphine
reinforcing properties
Rhesus monkeys, 493
N-allynormetazocine
oral self-administration
phencyclidine
withdrawal
Rhythmic slow activity, 177
ethanol
hippocampus
strain differences
Ritanserin, 853
d-amphetamine
conditioned place preference
diazepam
drug interactions
morphine
RO 4-46202, 613
citalopram
discriminative stimulus
drug comparisons
l-5-hydroxytryptophan
RO 5-4864, 749
central benzodiazepine agonist
clonazepam
drug comparisons
NaCl intake
peripheral benzodiazepine agonist
[3H] RO 5-4864 binding, 1015
heart
kidney
peripheral benzodiazepine receptors
stress
RO 15-4513
desipramine, 1045
differential sensitivity, 183
drug interactions, 501, 867
ethanol, 501, 867
ethanol antagonism, 183
ethanol intake, 1045
fluoxetine, 1045
food intake, 1045
GABAergic system, 501
light/dark choice paradigm, 867
molecular interactions, 501
staircase test, 867
strain differences, 183, 1045
water intake, 1045
Rotational behavior, 457
D_1/D_2 agonists
dopamine
EEDQ
selective protection
Route of administration, 309
amphetamine
cholecystokinin-octapeptide
hyperlocomotion
intra-accumbens injection
intracerebroventricular injection
stereotypy

Salivary cotinine, 895
human studies
marijuana smoke
serum cotinine
tobacco smoke
SCH 23390, 683
apomorphine
body temperature
haloperidol
Schedule-controlled behavior, 569
cholecystokinin
dose-dependent effects
rate-decreasing effects
Schedule-controlled performance, 1007
ionizing radiation
sublethal doses
Schedule-induced wheel running, 101
adrenalectomy
corticosterone
Scopolamine
acquisition, 949
amnesia, 1093
atropine, 625
chickens, 625
eight-arm radial maze, 119
immobility response, 625
nicotine, 119
paradoxical sleep suppression, 295
retention, 949
retrieval, 1093
SMS 201-995, 295
strain differences, 625
T-maze, 14-unit, 949
Seizures, 665
benzodiazepine receptor binding affinity
3-hydroxykynurenine
neonatal deficiency
vitamin B-6
Selective protection, 457
D_1/D_2 agonists
dopamine
EEDQ
rotational behavior
Self-stimulation
chronic administration, 515
cocaine, 1
l-dopa, 585
GABA agonists, 657
haloperidol, 585
imipramine, 1
interactive effects, 1
lateral hypothalamus, 657

rebound enhancement, 585
reward effect, 657
train-duration thresholds, 1
Self-stimulation reward, 589
catecholamines
drug interactions
endogenous opioids
ventral tegmental area
Semicarbazide, 337
bicuculline
flight behavior
microinjection
rats, detelencephalated
Serotonergic agonists, 617
discriminative stimulus
drug interactions
LSD
serotonergic antagonists
Serotonergic antagonists, 617
discriminative stimulus
drug interactions
LSD
serotonergic agonists
Serotonin, 37
drug interactions
lordosis
alpha-melanocyte stimulating hormone
Serotonin metabolism, brain, 715
d-fenfluramine
uptake inhibition
Serotonin receptors, 55
drug discrimination
drug interactions
dopamine receptors
ethanol
Serotonin uptake, 847
behavioral effects
5-methoxytryptamine
parachlorophenylalanine
prenatal exposure
Serotonin uptake inhibitor, 823
alcohol intake
renin-angiotensin system
Serum cotinine, 895
human studies
marijuana smoke
salivary cotinine
tobacco smoke
Sex differences
analgesia, 123
drug-admixed food method, 483
methaqualone, 483
morphine, 123
physical dependence, 483
prenatal stress, 123
Sexual behavior, 1021
rat, male
opioids
Shock controllability, 209
chlordiazepoxide
contextual fear
nociception
Shock-probe test, 1071
anxiolytics
buspirone
chlordiazepoxide
defensive burying
drug comparisons
Short-term treatment, 889
imipramine
long-term treatment
place preference, apomorphine-induced
place preference, food-induced
SKF 38393, 189
D1/D2 dopamine receptor stimulation
stereotyped behaviors
Skin mucus, 957
escape
frogs
tardive dyskinesia
Small groups, 539
human studies, males
marijuana
social behavior
SMS 201-995, 295
paradoxical sleep suppression
scopolamine
Social behavior, 539
human studies, males
marijuana
small groups
Spatial learning, 519
Morris Water Maze
pirenzepine
Spontaneous motor activity inhibition, 155
adenosine
cerebellum
ethanol
motor incoordination
Staircase test, 867
drug interactions
ethanol
light/dark choice paradigm
RO 15-4513
State-dependent memory, 83
human studies
nitrous oxide
Stereotyped behavior
amphetamine, 899
chronic administration, 899
D1/D2 dopamine receptor stimulation, 189
SKF 38393, 189
Stereotypy
amphetamine, 309, 535
cholecystokinin octapeptide, 309
circadian rhythm, 535
continuous administration, 535
hyperlocomotion, 309
intra-accumbens injection, 309
intracerebroventricular injection, 309
locomotor behavior, 535
route of administration, 309
Stimulation reward, 365
dopamine
lateral hypothalamus
neonatal depletions
rats, adult
Strain differences
acute administration, 769
acute pretreatment, 1065
adenosine receptors, 707
atropine, 625
autoradiography, 707, 781
brain regional uptake, 781
chickens, 625
2-deoxyglucose, 781
desipramine, 1045
differential antagonism, 183
dopamine D-1 receptors, 325
dopamine D-2 receptors, 325
ethanol, 177, 769, 781
ethanol antagonism, 183
ethanol intake, 1045
fluoxetine, 1045
food intake, 1045
hippocampus, 177
immobility response, 625
methylxanthines, 707
MHPG-SO_4
nicotine, 1065
noradrenaline metabolism, 769
plasma corticosterone levels, 1065
receptor density, 325
receptor distribution, 325
rhythmic slow activity, 177
RO 15-4513, 183, 1045
scopolamine, 625
water intake, 1045
Stress, 1015
heart
kidney
peripheral benzodiazepine receptors
[^{3}H] RO 5-4864 binding
Structure-activity studies, 403
carbamate esters
nicotine
nicotine agonists
nicotine antagonists
Sublethal doses, 1007
ionizing radiation
schedule-controlled performance
Substantia innominata, 679
benzodiazepine binding sites
in vitro autoradiography
Sulpiride, 917
drinking
eating
Supraspinal cerebral areas, 319
analgesia
intestinal inhibition
morphine

Tamoxifen, 829
aggressive behavior
medroxyprogesterone acetate
mice, male
Tardive dyskinesia, 957
escape, 957
frogs
skin mucus
T-cell antibody responses, 859
conditioned stimulus
cyclophosphamide
mice, female
unconditioned stimulus
Thyrotropin-releasing hormone, 941
brain, rat
hypothermia
Thyrotropin-releasing hormone binding, 73
behavioral effects
triazolobenzodiazepines
T-maze, 14-unit, 949
acquisition
retention
scopolamine
Tobacco dependence
human studies, 217
nicotine, 217
nicotine gum, 279
pharmacological effects, 217

pharmacological treatment, 279
Tobacco self-administration, 221
human studies
pharmacologic determinants
Tobacco smoke, 895
human studies
marijuana smoke
salivary cotinine
serum cotinine
Tolerance development, 755
amphetamine
anorectic effects
opiate mechanisms
U50488H
Tonic component, 1001
benzodiazepines
postdecapitation convulsions
Train-duration thresholds, 1
cocaine
imipramine
interactive effects
self-stimulation
Triazolobenzodiazepines, 73
behavioral effects
thyrotropin-releasing hormone binding

U50488H, 755
amphetamine
anorectic effects
opiate mechanisms
tolerance development
Unconditioned stimulus, 859
conditioned stimulus
cyclophosphamide
mice, female
T-cell antibody response
Unpunished responding
apomorphine, 753
buspirone, 723
drug comparisons, 723
gepirone, 723
8-hydroxy-2-(di-n-propylamino)tetralin, 723
pigeons, 723
punished responding, 753
Uptake inhibition, 715
d-fenfluramine
serotonin metabolism, brain

Ventral tegmental area, 589
catecholamines
drug interactions
endogenous opioids
self-stimulation reward
Visceral cortex, 693
aversive effects
dopamine innervation
lesions, 6-OHDA
opiates
Vitamin B-6, 665
benzodiazepine receptor binding affinity
3-hydroxykynurenine
neonatal deficiency
seizures

Water intake, 1045
desipramine
ethanol intake
fluoxetine
food intake
RO 15-4513
strain differences
Withdrawal, 493
N-allylnormetazocine
oral self-administration
phencyclidine
rhesus monkeys

AUTHOR INDEX

Abood, L. G., 403
Agmo, A., 1021
Aicher, S. A., 65
Allen, J. L., 625
Amir, S., 905
Anderson, S. M., 169
Artinián, J., 899
Asin, K. E., 577
Aulakh, C. S., 451
Azar, A. P., 925
Azmitia, E. C., 847

Backus, L. I., 657
Bagri, A., 337
Baldwin, H. A., 809
Barrett, J. E., 723
Barthalmus, G. T., 957
Basile, A. S., 1015
Bassett, J. R., 391
Bechara, A., 687, 693
Bednarz, L. M., 189
Belzung, C., 867
Bendani, T., 397
Beninger, R. J., 525
Benowitz, N. L., 249
Benson, R. W., 859
Benvenga, M. J., 205
Bernardis, L. L., 649
Block, L. D., 665
Boggan, W. O., 31
Boja, J. W., 1085, 1089
Bostwick, M., 255
Boyd, S., 31
Branch, M. N., 737
Brandão, M., 337
Bree, M. P., 977
Bridges, R. S., 123
Brooderson, R. J., 189
Brown, R. L., 543
Bruno, J. P., 365

Cabib, S., 143, 765
Calcagnetti, D. J., 817
Calligaro, D., 163
Campbell, I. C., 299, 347
Cancela, L. M., 899
Cappell, H., 515
Carino, M. A., 115
Carrive, P., 337
Carroll, M. E., 493
Cazala, P., 397
Chachich, M. E., 949
Chan, A. W. K., 385
Chaturvedi, A. K., 1035
Chinn, C., 115
Chipkin, R. E., 683
Choi, W. W., 83
Clark, M., 155
Clark, V. A., 895
Co, C., 1051
Collins, A. C., 269, 1059
Compton, D. R., 371
Cook, J. M., 243
Cool-Hauser, V. A., 433
Corrigall, W. A., 443, 787
Coulaud, H., 89
Craft, R. M., 775
Cramer, C. P., 817
Crawley, J. N., 129, 1015
Cushing, L. L., 343

D'Agata, V., 961
Dall'olio, R., 463
Danguir, J., 295
Dar, M. S., 155
De Robertis, E., 331
De Saint-Hilaire-Kafi, S., 295
Desan, P. H., 21, 563
Domae, M., 1081
Domer, F. R., 543
Donzanti, B. A., 795
Drago, F., 961
Drugan, R. C., 1015
Dunn, G., 299, 347
Durcan, M. J., 299, 347
Dworkin, S. I., 1051
Dyer, R. S., 421
Dymshitz, J., 905

Edinger, H. M., 409
Elgin, R. J., Jr., 137
Engel, J. A., 471
Ettenberg, A., 309
Evans, R. L., 753
Even, P., 89

Falk, J. L., 749
Fanselow, M. S., 817
Faught, K., 31
Feldman, M. J., 649
Feldon, J., 871
Fibiger, H. C., 835
File, S. E., 809
Fischman, M. W., 539
Fleck-Kandath, C., 723
Foltin, R. W., 539
Fraile, I. G., 729
Frampton, S. F., 417
Frank, R. A., 1
Franz, C. G., 1007
Freedman, D. X., 427
Freund, R. K., 1059
Fulginiti, S., 899
Fuller, R. W., 715
Fundytus, M., 1071
Furukawa, T., 1081

Gähwiler, M., 199
Gandolfi, O., 463
Gatta, F., 5
Gerhardt, G. A., 1077
Geyer, M. A., 417
Ghoneim, M. M., 83
Giagnoni, G., 319
Gianoulakis, C., 933
Glennon, R. A., 597
Goeders, N. E., 1051
Gogas, K. R., 791
Goldberg, S. R., 215, 217, 221, 227, 243
Goodale, D. B., 457
Gori, E., 319
Gormezano, I., 433
Grant, S. J., 13
Gratton, A., 1077
Greenblatt, D. J., 511
Greenwood, C., 693
Grinker, J. A., 925
Grupp, L. A., 823
Guerin, G. F., 1051
Guilarte, T. R., 665

Haertzen, C. A., 967
Hagen, T. J., 243

Hara, T., 1001
Harding, J. W., 343
Harrison, J. R., 1007
Harvey, J. A., 433
Hawkins, M., 303
Hellevuo, K., 183
Helmstetter, F. J., 817
Hennig, C. W., 625
Henningfield, J. E., 129, 217, 221, 227, 279
Herberg, L. J., 585
Hernandez, L., 917
Herning, R. I., 129
Hesse, G. W., 657
Hill, J. L., 451
Hiltunen, A. J., 675
Hjorth, S., 189
Hoebel, B. G., 917
Hoffer, B. J., 1077
Hollingsworth, E. M., 535
Hook, R., 255
Horita, A., 115
Hough, L. B., 791
Howard, J. L., 775
Huang, Y. H., 13
Hubner, C. B., 195
Hunt, T., 515
Hunter, A. J., 519
Hutchison, W. D., 933

Ichihara, K., 107
Ida, Y., 769
Ignatius, J., 177
Inanaga, K., 769
Ingram, D. K., 949
Iwamoto, E. T., 119

Jacob, J., 657
Jacob, P., III, 249
Jacobi, A. G. M., 457
Järbe, T. U. C., 675
Jarvik, J. E., 279
Jarvis, M. F., 707
Jasinski, D. R., 967
Jensen, L. L., 343
Johnson, R. E., 967
Johnston, A. L., 809
Judge, M. E., 77
Jungschaffer, D. A., 1059

Kaheinen, P., 177
Kalant, H., 933
Kalin, N. H., 801
Kameyama, T., 107
Kant, G. J., 169
Katz, J. L., 243
Kawazawa, S., 1001
Kerr, L. M., 325
Khazan, N., 163
Kinsley, C. H., 123
Klitenick, M. A., 577
Kodis, M., 649
Koike, Y., 483
Kornetsky, C., 195
Korpi, E. R., 177, 183, 781
Korttila, K., 83
Koshikawa, N., 347
Kozlowski, M. R., 73
Kulkarni, S. K., 501
Kumor, K. M., 967
Kuntz, D. J., 1035

Langan, M. C., 385
Leibowitz, S. F., 925
Leidenheimer, N. J., 351
Leo, P., 77, 1093
Leong, F. W., 385
Leu, J. R., 169
Li, T.-K., 1045
Lichtensteiger, W., 199
Lin, W., 101
Lindroos, F., 781
Linseman, M. A., 787
Lister, R. G., 701
Long, R., 129
Lopez, F., 511
Lozada, M., 635
Lubow, R. E., 871
Lukas, S. E., 977
Lumeng, L., 1045
Lyddane, J. E., 371
Lyon, R. A., 597

McBride, W. J., 1045
McEwen, B. S., 729
McEwen, G., 649
McIntire, K. D., 45
McIntyre, J. F., 625
McIntyre, T., 911
McMillan, D. E., 753
McNicholas, L. F., 945
McWilliam, J. R., 299

Maier, S. F., 21, 563
Maiti, A., 403
Maldonado, H., 635
Mann, P. E., 123
Mansbach, R. S., 723
Mantysalo, S., 177
Marks, M. J., 269
Martin, B. J., 1059, 1065
Martin, B. R., 371
Martin, G. E., 137
Martin, G. M., 687
Martin, W. R., 255, 945
Martin-Iverson, M. T., 835
Massi, P., 319
Massotti, M., 5
Matsumoto, S., 1081
Matsuo, N., 1081
Matthews, A., 543
Mazurski, E. J., 525
Medina, J. H., 331
Mehrabani, P. A., 391
Mehta, A. K., 995
Mele, L., 5
Mele, P. C., 1007
Mello, N. K., 977
Mendelson, J. H., 977
Mewaldt, S. P., 83
Middaugh, L. D., 31
Miller, L. G., 511
Miner, L. L., 269
Mintz, M., 585
Misawa, M., 483
Misslin, R., 867
Miyazaki, M., 941
Mizobe, T., 941
Mizuki, Y., 1001
Montanaro, N., 463
Moriarty, D. D., Jr., 625
Mueller, K., 535
Munday, W. R., 119

Murphy, D. L., 451
Murphy, J. M., 1045
Muscat, R., 641

Nabeshima, T., 107
Neale, M. C., 299
Nencini, P., 755
Nicolaidis, S., 89
Nitz, D., 1
Nomikos, G. G., 853
Novas, M. L., 331

Oguchi, M., 769
Okuda, C., 941
Overton, D. A., 879

Papasava, M., 101
Papp, M., 889
Pappas, B. A., 479
Parada, M. A., 917
Paredes, R., 1021
Parolaro, D., 319
Patrini, G., 319
Paul, S. M., 511, 1015
Paule, M. G., 859
Penetrante, M. L., 385
Perlanski, E., 823
Perry, M., 829
Peters, D. A. V., 669
Petersen, R. C., 83
Pfaff, D. W., 729
Picerno, J. M., 625
Picker, M., 603
Pickworth, W. B., 129
Pisa, M., 835
Plaessmann, W. R., 749
Pollard, G. T., 775
Pommering, T., 1
Poulos, C. X., 515
Pravica, M., 303
Puglisi-Allegra, S., 143, 765
Pyykko, I., 177

Quartermain, D., 77, 1093

Rabin, R. A., 613, 617
Radulovacki, M., 303
Raible, L., 37
Randich, A., 65
Redmond, D. E., Jr., 13
Ribary, U., 199
Rigdon, G. C., 421
Riley, A. L., 569
Roberts, D. W., 859
Roberts, F. F., 519
Robertson, D. W., 715
Romano, A., 635
Roncada, P., 463
Rose, I. C., 585
Rosellini, R. A., 209
Ryan, C. L., 479
Ryan, S. M., 563

Sahid Salles, K., 403
Sala, M., 319
Sarter, M., 679
Satoh, H., 769
Scalisi, B., 961
Scapagnini, U., 961
Schanley, D. L., 385
Schechter, M. D., 55, 351, 1085, 1089

Schindler, C. W., 433
Schlumpf, M., 199
Schmitt, P., 337
Schneider, H. H., 679
Schulze, G. E., 859
Seifert, W. F., 589
Seran, G. F., 357
Seyfried, D. M., 457
Shader, R. I., 511
Shaikh, M. B., 409
Shashoua, V. E., 657
Shemer, A., 847
Shen, C. F., 879
Sherman, J. E., 801
Shirakawa, K., 1081
Shirao, I., 769
Shor-Posner, G., 925
Shreve, P. E., 379
Shulgin, A. T., 249
Siegel, A., 409
Siegel, S., 427
Signs, S. A., 55
Silbert, L. H., 21
Simmons, M., 895
Simon, N. G., 829
Singer, G., 101
Sizemore, G. M., 737
Skirboll, L. R., 129
Skolnick, P., 911, 1015
Sloan, J. W., 255, 945
Smith, J. E., 1051
Smock, T. K., 563
Smythe, J. W., 479
Snoddy, H. D., 715
Söderpalm, B., 471
Spangler, E. L., 949
Sparber, S. B., 357
Spaulding, T. C., 205
Spyraki, C., 853
Stein, E. A., 983
Stellar, J. R., 365, 657
Stewart, R. B., 823
Stivers, J. A., 129
Stolerman, I. P., 235
Suzuki, T., 483

Takada, K., 243
Tanaka, M., 769
Tang, M., 749
Tanzer, D. J., 309
Tashkin, D. P., 895
Thomas, B. F., 371
Ticku, M. K., 501, 995
Titeler, M., 597
Tomaz, C., 337
Towell, A., 641
Treit, D., 1071
Trifunovic, R., 529
Trullas, R., 911
Trusk, T. C., 983
Tsuda, A., 769
Tsujimaru, S., 769

Ullman, E. A., 1059
Unis, A. S., 325
Uretsky, N. J., 379
Ushijima, I., 1001

Vaccarino, F. J., 443
Vaccheri, A., 463
Valerio, C., 961

van der Kooy, D., 687, 693
Van Ree, J. M., 589
Van Vunakis, H., 895
Van Wolfswinkel, L., 589
Vogel, E., 867
Volpe, M., 925

Wachtel, S. R., 189
Wagner, H. N., Jr., 665
Wala, E., 255, 945
Wamsley, J. K., 325
Wängdahl, K., 675
Waraczynski, M., 365
Warren, D. A., 209
Wehner, J. M., 1065
Weiner, I., 871
Weiss, B., 457
Weiss, F., 309
Wessler, G., 543
Whitaker-Azmitia, P. M., 847
White, F. J., 189
Wilks, L. J., 809
Williams, M., 707
Willner, P., 641
Winsauer, P. J., 569
Winter, J. C., 613, 617
Wirtshafter, D., 529, 577
Wise, R. A., 1077
Wolfman, C., 331
Woodmansee, W. W., 563
Wozniak, K. M., 451
Wright, J. W., 343

Yamada, K., 1081
Yamada, M., 1001
Yamamoto, B. K., 795
Young, G. A., 163, 489

Zielinski, W. J., 957
Zito, K. A., 693